News Category
In vitro ADME studies are critical for early evaluation of drug candidates, helping to avoid costly late-stage failures and expedite the development o...
A new study reveals that the risk of sepsis, meningitis, or pneumonia from air pollution depends on individual bacterial strains, highlighting the nee...
Peptide Wholesale Supply now provides HPLC chromatographic data with every bulk order of BPC-157, Semaglutide, and Tirzepatide, enhancing analytical t...
New guidance from experts emphasizes that small cell lung cancer patients should ask about clinical trials at their first appointment, as emerging the...
GeoVax has secured access to CEPI's Centralised Laboratory Network for independent testing of its MVA-based mpox vaccine candidate, GEO-MVA, in a pivo...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities to help researchers engineer targeted and stimul...
BioCorRx adds a former White House drug policy leader to its advisory board, a move that could strengthen its positioning in addiction treatment polic...
Regentis Biomaterials has treated 43 of 80 patients in its Phase III GelrinC trial and received European approval for a manufacturing process that inc...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protecting drug, receives FDA clearance for Phase 2 trial, potentially revolutionizing multiple ...
Regentis Biomaterials is advancing GelrinC, a hydrogel implant designed to regenerate knee cartilage, as a potential alternative to symptom management...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer signals a strategic push to advance its BiTAC® technology and oncology...
Quantum BioPharma's Lucid-MS, a novel non-immune-suppressing multiple sclerosis therapy, advances toward Phase 2 trials after FDA IND clearance, poten...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS represents a historic shift in multiple sclerosis treatment, moving beyond immune su...
Quantum BioPharma receives FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to shield and potent...
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference, highlighting the...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets the DNA repair enzyme PNKP and uses two selectivity mechanisms...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially ...
The article highlights the overlooked diagnostic challenges and severe impacts of recurrent urinary tract infections in women, emphasizing the urgent ...
Silo Pharma's participation in the IPAC-RS 2026 forum underscores its commitment to advancing SPC-15, a nose-to-brain treatment for PTSD, with promisi...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a significant milestone for a novel approach to multiple sclerosis treatment, poten...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective drug candidate, has received FDA clearance to begin a Phase 2 trial, a rare milestone...
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's potential to enhance supply diversity and preparedness.
VERAXA Biotech's appointment of Raju Willener as CFO signals a strategic move to strengthen its financial leadership and advance its oncology pipeline...
Scinai Immunotherapeutics strategically terminates its PC111 license with PinCell to concentrate on its NanoAb platform and CDMO business, aiming to p...
Onco-Innovations advances its oncology pipeline by building manufacturing readiness, IND-enabling activities, and financial support, reducing executio...
Quantum BioPharma's FDA clearance for Lucid-MS phase 2 trial introduces a first-in-class myelin repair approach that could transform MS treatment by p...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy (LITT) as a less invasive alternative to open...
Ocumetics Technology Corp. initiates patient recruitment for the second group of its human clinical study, advancing beyond safety to evaluate vision ...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS marks a historic step toward a first-in-class therapy targeting myelin repair, poten...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Pan African Clinical Trials Registry, marking a critical step in ...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug candidate for multiple sclerosis that targets...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial for Lucid-MS, a first-in-class drug targeting demyelination, signals a potential paradigm s...
Quantum BioPharma's FDA clearance to initiate a Phase 2 trial of Lucid-MS marks a pivotal step toward a targeted therapy for multiple sclerosis, poten...
Tonix Pharmaceuticals' promotion of Thomas Englese to CCO underscores its strategic focus on commercializing TONMYA, the first new fibromyalgia treatm...
A large cohort study reveals that the timing of brain metastasis development significantly impacts survival in colorectal cancer patients, highlightin...
Onco-Innovations has moved its lead PNKP inhibitor ONC010 closer to human trials by achieving high-purity API production and establishing a regulatory...
OS Therapies' participation in the Moody Capital conference underscores its strategic positioning ahead of critical regulatory decisions for its lead ...
A Swiss-led preclinical study reveals that administering immunotherapy before surgery significantly improves glioblastoma treatment outcomes, offering...
The FDA's failure to aggressively enforce laws against online sales of the investigational drug retatrutide has allowed a dangerous black market to th...
A Mass General Brigham study finds that unintended radiation to the thymus during lung cancer treatment is associated with poorer clinical outcomes, h...
Tonix Pharmaceuticals' participation in the Cantor conference highlights its strategic focus on CNS and immunology advancements, including its newly a...
NurExone Biologic's participation at the Moody Capital Solutions conference highlights its exosome-based therapies and strategic U.S. manufacturing pl...
CNS Pharmaceuticals' Chief Business Officer discusses the company's strategic focus on oncology and neurology with best-in-class potential, highlighti...
Salman Fazal, MD, a hematologist and stem cell transplant expert at UPMC Hillman Cancer Center in Harrisburg, has been named a 2026 Castle Connolly To...
Quantum BioPharma's Lucid-MS drug candidate for progressive multiple sclerosis has attracted a 'Buy' rating and $8.00 price target from Rodman & Rensh...
NanoViricides is moving its measles drug candidate NV-387 into Phase II trials, leveraging FDA designations that could expedite development and offer ...
TransCode Therapeutics' lead candidate TTX-MC138 showed significant survival benefits and reduced miR-10b expression in a preclinical breast cancer bo...
